Health Care/Hospital

Cognos Therapeutics, Inc. to Become Publicly Listed on Nasdaq via Business Combination with Nocturne Acquisition Corporation

* Cognos Therapeutics is a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and str...

2023-01-05 07:10 3601

CGTN: China's preparedness for adjusting its COVID-19 policies

BEIJING, Jan. 5, 2023 /PRNewswire/ -- Since China prioritized its COVID-19 response from the dynamic zero-COVID policy, some Western media and intellectuals have been questioningChina's "preparedness" of making the change. Preparedness can ...

2023-01-05 04:07 1682

Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...

2023-01-05 00:00 2318

IMG Welcomes Scott Ackerman as Chief Commercial Officer

INDIANAPOLIS, Jan. 4, 2023 /PRNewswire/ -- International Medical Group® (IMG®), an award-winning global insurance benefits and assistance services company, is pleased to introduceScott Ackerman as the company's new Chief Commercial Officer. Scott joins the IMG team with 30 years of experience in ...

2023-01-04 22:00 1994

NuraLogix Announces 'Holy Grail' of Blood Pressure Measurement

LAS VEGAS, Jan. 4, 2023 /PRNewswire/ -- Researchers at NuraLogix, a global leader in Health Tech AI, announced today that they have achieved the 'Holy Grail' of contactless blood pressure (BP) measurement using the company's TOI™ based Anura™ app!

2023-01-04 22:00 1790

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

* Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies * Synaffix to receive up to $150m in upfront and milestone payments plus royalties  SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused ...

2023-01-04 21:00 2267

Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment

Study met all primary endpoints ANNAPOLIS, Md., Jan. 4, 2023 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today positive results from the first cohort of its Phase 2a clinical trial of AB-101a, a topical the...

2023-01-04 20:30 1904

China's optimization of control measures lays solid foundation for COVID-19 response

BEIJING, Jan. 4, 2023 /PRNewswire/ -- A report from People's Daily: Local authorities and relevant departments inChina have been making unremitting efforts recently to ensure the supply of medical resources, satisfy the demand for medicines and focus on the prevention and treatment of high-risk g...

2023-01-04 15:39 2157

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

SHANGHAI, Jan. 4, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform, announced the appointment of Dr.Mingdong Zhang to the company's Scientific Advisory Board (SAB). Dr. Zhang will provide guidance on Pulnovo Medical's clinical development and registration strategya...

2023-01-04 10:46 1966

Bioniq® Repair Toothpaste with 20% BioHAP*, scientifically proven to remineralise enamel and keeps teeth healthy and strong

HONG KONG, Jan. 4, 2023 /PRNewswire/ -- While most Westerners prefer trimmed meat and fish fillets, a vast majority of Asian diners enjoy eating their food off bones, picking flesh from carcasses, and gnawing on tendons,cartilage, and bones for gooey, chewy textures1. Hong Kong, a food paradise ...

2023-01-04 10:00 3282

Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that TST003, its first...

2023-01-04 08:00 2229

Exclusive Pepaminto topper wins CES® 2023 Innovation Award

Mattress Topper developed exclusively for the Apple Watch®. MÜNSTER, Germany, Jan. 3, 2023 /PRNewswire/ -- Freezing, shivering, sweating - everyone's nighttime perception of warmth is different. The German Start-up Variowell Development asked 3.300 consumers in 5 countries globally. Over 50% ans...

2023-01-03 22:00 2077

Sisram Medical to Present Virtually at the 25th Annual Needham Growth Conference

CAESAREA, Israel, Jan. 3, 2023 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group featuring a first-of-its-kind synergistic ecosystem of business building blo...

2023-01-03 21:30 1130

Call for Application for 2023 Tsinghua Amgen Scholars Program

BEIJING, Jan. 3, 2023 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Thro...

2023-01-03 21:20 1048

Steakholder Foods® Receives Grant of up to $1M for Collaboration with Umami Meats to 3D Bio-Print Structured Cultivated Fish Products

The company's collaborative initiative with its 3D bio-printer is a significant step forward in the company's commercialization strategy for 2023 REHOVOT, Israel, Jan. 3, 2023 /PRNewswire/ -- Steakholder Foods (Nasdaq: STKH), an international deep-tech food company at the forefront of the cultiv...

2023-01-03 20:00 3000

Clarivate and the Chinese Academy of Sciences Release Annual Joint Report to Identify 165 Research Fronts

Selecting significant research specialties in sciences and social sciences LONDON, Jan. 3, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, and theChinese Academy of Sciences (CAS) today released R...

2023-01-03 16:02 1791

Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company

--Focus on renal disease and mRNA platform portfolios-- --Build out commercialization capabilities in preparation for the potential approval and launch of Nefecon and Xerava inChina in 2023-- --Leverage both in-house discovery and strategic business development to establish industry leadership ...

2023-01-03 16:00 3013

Bayer Taiwan Company Ltd. and Berocca Honored at the Asia Pacific Enterprise Awards 2022 Taiwan

SINGAPORE, Jan. 3, 2023 /PRNewswire/ -- The Asia Pacific Enterprise Awards (APEA) 2022 Taiwan is pleased to honor 34 outstanding business leaders and enterprises for their commendable dedication toward spearheadingTaiwan's economic recovery and development. Presented by leading regional NGO Enter...

2023-01-03 10:05 1288

CGTN: China monitors coronavirus mutations to adjust COVID-19 response

BEIJING, Jan. 3, 2023 /PRNewswire/ -- With China loosening its COVID-19 restrictions, some experts have expressed concern thatChina's relaxation of COVID-19 limitations will enhance the likelihood of the virus mutating. "It is a worry," said CNN, citing William Schaffner, professor at the Divisi...

2023-01-03 08:27 1465

CStone announces the registrational clinical trial of sugemalimab as first-line treatment in patients with esophageal squamous cell carcinoma met primary endpoints and plans to submit a supplemental NDA to NMPA

* Sugemalimab became the first anti-PD-L1 monoclonal antibody that achieved positive results in the study of patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. * Sugemalimab in combination with chemotherapy demonstrated a statistically ...

2023-01-03 08:10 2895
1 ... 128129130131132133134 ... 553